Associated Papers
Non-Isolated Dandy-Walker Malformation: Exome Sequencing Efficacy and Phenotypic Expansions.
Araji S et al.
Clinical Genetics, 2026
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.
Castañeda-González JP et al.
Clinical Lung Cancer, 2025
Single nucleotide variants in lung cancer.
Tian X et al.
Chinese Medical Journal Pulmonary and Critical Care Medicine, 2024
Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Whitley MJ et al.
Science Advances, 2024
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Ansari-Pour N et al.
Blood, 2023
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Sivakumar S et al.
Nature Communications, 2022
Markov State Models and Molecular Dynamics Simulations Reveal the Conformational Transition of the Intrinsically Disordered Hypervariable Region of K-Ras4B to the Ordered Conformation.
Zhang H et al.
Journal of Chemical Information and Modeling, 2022
A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.
Zhang SS et al.
Jto Clinical and Research Reports, 2022
Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E et al.
Cancer Gene Therapy, 2022
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.
Feng S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C et al.
Cancer Discovery, 2022
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Tran TH et al.
Blood Advances, 2022
KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.
Vendramini E et al.
Cancers, 2022
Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.
Tripathi S et al.
Computational and Structural Biotechnology Journal, 2022
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Loree JM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Embryonic Expression of NrasG 12 D Leads to Embryonic Lethality and Cardiac Defects.
You X et al.
Frontiers in Cell and Developmental Biology, 2021
Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies.
Li Z et al.
Clinical and Translational Medicine, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild-type TP53 and mutant KRAS, G3BP1 and IL7R.
Goldgraben MA et al.
Pediatric Blood & Cancer, 2020
Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts.
Dunnett-Kane V et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2020
GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R.
Bera AK et al.
Birth Defects Research, 2020
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B et al.
Blood, 2020
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S et al.
Frontiers in Oncology, 2020
Atypical RAS Mutations in Metastatic Colorectal Cancer.
Pietrantonio F et al.
Jco Precision Oncology, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Tajan M et al.
Endocrine Reviews, 2018
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM et al.
Oncotarget, 2016
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
Identification of an oncogenic RAB protein.
Wheeler DB et al.
Science (new York, N.y.), 2015
Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation.
Šolman M et al.
Elife, 2015
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
A lethal course of hypertrophic cardiomyopathy in Noonan syndrome due to a novel germline mutation in the KRAS gene: case study.
Nosan G et al.
Croatian Medical Journal, 2013
Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.
Cirstea IC et al.
Human Molecular Genetics, 2013
Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development.
Mukhopadhyay A et al.
Developmental Biology, 2013
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB et al.
Cancer Discovery, 2012
Two novel germline KRAS mutations: expanding the molecular and clinical phenotype.
Stark Z et al.
Clinical Genetics, 2012
Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey.
Abe Y et al.
American Journal of Medical Genetics. Part A, 2012
Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.
Gremer L et al.
Human Mutation, 2011
Noonan syndrome: clinical aspects and molecular pathogenesis.
Tartaglia M et al.
Molecular Syndromology, 2010
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
Rauen KA et al.
American Journal of Medical Genetics. Part A, 2010
Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.
Lo FS et al.
European Journal of Pediatrics, 2009
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Tyner JW et al.
Blood, 2009